INNATE PHARMA SA-SPONS ADR (IPHA) Forecast, Price Target & Analyst Ratings

NASDAQ:IPHA • US45781K2042

Current stock price

1.59 USD
-0.07 (-4.22%)
At close:
1.51 USD
-0.08 (-5.03%)
Pre-Market:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INNATE PHARMA SA-SPONS ADR (IPHA).

Forecast Snapshot

Consensus Price Target

Price Target
$7.01
+ 341.09% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q2 / 2026
EPS Estimate
-€0.07
Revenue Estimate
7.817M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.50%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$7.01
Upside
+ 341.09%
From current price of $1.59 to mean target of $7.01, Based on 8 analyst forecasts
Low
$6.89
Median
$7.01
High
$7.28

Price Target Revisions

1 Month
-5.31%
3 Months
-4.66%

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for IPHA. The average price target is 7.01 USD. This implies a price increase of 341.09% is expected in the next year compared to the current price of 1.59.
The average price target has been revised downward by 4.66% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

IPHA Current Analyst RatingIPHA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4

Analyst Ratings History

IPHA Historical Analyst RatingsIPHA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
82.50%
IPHA was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about IPHA.
In the previous month the buy percentage consensus was at a similar level.
IPHA was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-07HC Wainwright & Co.Reiterate Buy -> Buy
2025-10-29BTIGReiterate Buy -> Buy
2025-10-29HC Wainwright & Co.Upgrade Neutral -> Buy
2025-09-18Leerink PartnersDowngrade Outperform -> Market Perform
2025-09-18HC Wainwright & Co.Downgrade Buy -> Neutral
2025-04-24HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-28HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-06HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-17HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-09HC Wainwright & Co.Reiterate Buy -> Buy
2024-11-15HC Wainwright & Co.Reiterate Buy -> Buy
2024-11-12HC Wainwright & Co.Reiterate Buy -> Buy
2024-09-13HC Wainwright & Co.Reiterate Buy -> Buy
2024-06-12HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-15HC Wainwright & Co.Reiterate Buy -> Buy
2024-04-11HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-22HC Wainwright & Co.Reiterate Buy -> Buy
2023-11-15HC Wainwright & Co.Reiterate Buy -> Buy
2023-09-18HC Wainwright & Co.Reiterate Buy -> Buy
2023-06-16HC Wainwright & Co.Reiterate Buy -> Buy
2023-03-24HC Wainwright & Co.Reiterate Buy
2022-11-15SVB LeerinkMaintains Outperform
2022-09-16CitigroupMaintains Buy
2022-08-02SVB LeerinkMaintains Outperform
2022-05-11SVB LeerinkMaintains Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q2 / 2026
EPS Estimate
-€0.07
Revenue Estimate
7.817M
Revenue Q2Q
367.80%
EPS Q2Q
72.00%
Number of Analysts
2

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
-5.99%
EPS (3 Months)
-4.23%

Next Earnings Summary

The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
IPHA revenue by date.IPHA revenue by date.
51.901M
4.68%		12.622M
-75.68%		2.787M
-77.92%		25.246M
805.85%		15.7M
-37.81%		57.572M
266.70%		195.72M
239.96%		172.79M
-11.72%		224.02M
29.65%		263.64M
17.69%		440.9M
67.24%
EBITDA
YoY % growth
IPHA ebitda by date.IPHA ebitda by date.
-7.578M
-126.15%		-49.581M
-554.28%		-49.735M
-0.31%		102.01M
305.11%		228.26M
123.76%		N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
IPHA ebit by date.IPHA ebit by date.
-12.669M
22.87%		-51.575M
-307.10%		-51.119M
0.88%		34.614M
167.71%		-61.384M
-277.34%		-65.419M
-6.57%		42.009M
164.22%		65.393M
55.66%		105.74M
61.70%		134.71M
27.40%		N/A
Operating Margin
IPHA operating margin by date.IPHA operating margin by date.
-24.41%-408.61%-1,834.19%137.11%-390.98%-113.63%21.46%37.85%47.20%51.10%N/A
EPS
YoY % growth
IPHA eps by date.IPHA eps by date.
N/A
-169.82%		N/A
23.22%		N/A
-35.80%		-0.47
13.33%		-0.95
-101.40%		-0.78
17.71%		N/AN/AN/AN/AN/A

All data in EUR

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.07
72.00%		-0.13
-8.33%		-0.10
16.67%		-0.13
76.13%		-0.13
-85.71%		-0.09
30.77%		-0.13
-30.00%
Revenue
Q2Q % growth		7.817M
367.80%		2.293M
15.81%		2.404M
115.41%		2.353M
-15.66%		2.788M
-64.33%		9.878M
330.79%		6.989M
190.72%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-8.211M
67.71%		-13.645M
-6.13%		-16.17M
37.06%		-19.766M
-51.82%		-19.443M
-136.78%		-14.685M
-7.62%		-19.917M
-23.17%

All data in EUR

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6 -0.8

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-12.83%
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
30.65%
Revenue Next 5 Year
46.26%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

INNATE PHARMA SA-SPONS ADR / IPHA Forecast FAQ

What is the average price target for INNATE PHARMA SA-SPONS ADR (IPHA) stock?

8 analysts have analysed IPHA and the average price target is 7.01 USD. This implies a price increase of 341.09% is expected in the next year compared to the current price of 1.59.

Can you provide the consensus estimates for INNATE PHARMA SA-SPONS ADR next earnings?

The consensus EPS estimate for the next earnings of INNATE PHARMA SA-SPONS ADR (IPHA) is -0.07 USD and the consensus revenue estimate is 7.82M USD.

Can you provide the analyst count for INNATE PHARMA SA-SPONS ADR stock?

The number of analysts covering INNATE PHARMA SA-SPONS ADR (IPHA) is 8.